查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611366

思覺失調症治療藥物市場：按治療層級、劑量方法和分銷管道 - 全球預測 2025-2030

Schizophrenia Therapeutics Market by Therapeutic Class (Second Generation, Third Generation), Administration (Injectable, Oral), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年思覺失調症治療藥物市場價值為78.9億美元，預計到2024年將達到80.8億美元，複合年成長率為4.94%，到2030年將達到110.6億美元。

思覺失調症藥物市場包括多種治療方法，包括抗精神病藥物、心理治療和旨在控制思覺失調症症狀（如妄想、幻覺和認知障礙）的生活方式調整。思覺失調症是一種慢性且嚴重的疾病，通常始於青春期晚期和成年早期，需要長期治療策略來改善患者的生活品質。應用範圍涵蓋醫院、診所和復健中心，影響患者、看護者和醫療保健提供者等最終用戶。成長要素包括診斷率的提高、新藥和治療方法研究的增加以及公眾心理健康意識的提高。精神疾病盛行率的上升，加上對精神疾病去人格化的持續努力，可能會推動市場擴張。為抗治療性患者開發標靶治療方法以及整合人工智慧主導的診斷和監測系統等數位技術，可以個人化和最佳化治療方法，正在開闢新的機會。然而，該市場受到多種挑戰的限制，包括開發新治療方法的高成本、現有藥物的副作用以及某些地區獲得精神衛生保健的機會有限。此外，與精神疾病相關的恥辱也是阻礙患者治療性介入的因素。從創新的角度來看，潛在的機會包括開發副作用較少的下一代抗精神病藥物、基因組學的進步以提供客製化治療，以及使用行動醫療應用程式來追蹤治療依從性和患者進展，這被認為是一個重大成長。此外，製藥公司、科技公司和醫療保健提供者之間的相互合作可以促進進步並消除市場障礙。持續的市場研究和應對監管變化對於在這個充滿活力的重要行業中獲得市場佔有率和實現持續成長至關重要。

主要市場統計
基準年[2023] 78.9億美元
預計年份 [2024] 80.8億美元
預測年份 [2030] 110.6億美元
複合年成長率（%） 4.94%

市場動態：快速發展的思覺失調症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變思覺失調症藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球思覺失調症患者數量增加
    • 政府提高對精神疾病認知的措施和宣傳活動
    • 持續研究開發高效思覺失調症治療藥物
  • 市場限制因素
    • 治療費用上漲且缺乏保險覆蓋
  • 市場機會
    • 日益關注個人化醫療以提高思覺失調症患者的藥物療效
    • 思覺失調症的治療方法進展
  • 市場挑戰
    • 與思覺失調症藥物相關的副作用

波特的五力：駕馭思覺失調症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對思覺失調症藥物市場的影響

外部宏觀環境因素在塑造思覺失調症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解思覺失調症治療藥物市場的競爭狀況

對思覺失調症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV思覺失調症藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估思覺失調症治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃思覺失調症治療藥物市場的成功之路

思覺失調症治療藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地思覺失調症的發生率正在上升
      • 政府提高人們對精神健康障礙意識的措施和宣傳活動
      • 持續研究發展思覺失調症的有效治療方法
    • 抑制因素
      • 治療費用上漲和保險覆蓋率低
    • 機會
      • 更重視個人化醫療以提高思覺失調症患者的藥物療效
      • 思覺失調症的治療和治療方法進展
    • 任務
      • 與思覺失調症藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級的思覺失調症治療藥物市場

  • 第二代
  • 第三代

第7章思覺失調症治療藥物市場管理按市場管理

  • 可注射的
  • 口服

第8章思覺失調症管道

  • 醫院
  • 藥局
    • 離線
    • 線上

第9章 北美和南美思覺失調症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區思覺失調症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的思覺失調症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Allergan Plc by AbbVie Inc.
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb and Company
  • Delpor, Inc.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • Johnson & Johnson Services, Inc.
  • Karuna Therapeutics Inc
  • Lundbeck A/S
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Neurocrine Biosciences, Inc.
  • Otsuka America Pharmaceutical Inc.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vanda Pharmaceuticals Inc.
Product Code: MRR-8E22B61932B8

The Schizophrenia Therapeutics Market was valued at USD 7.89 billion in 2023, expected to reach USD 8.08 billion in 2024, and is projected to grow at a CAGR of 4.94%, to USD 11.06 billion by 2030.

The schizophrenia therapeutics market encompasses a wide range of treatments including antipsychotic medications, psychotherapy, and lifestyle adjustments aimed at managing schizophrenia symptoms - such as delusions, hallucinations, and cognitive difficulties. Necessity arises from the chronic and severe nature of the disorder, typically emerging in late adolescence or early adulthood, thereby demanding long-term treatment strategies to improve patient quality of life. Applications span across hospitals, clinics, and rehabilitation centers, impacting end-users such as patients, caregivers, and healthcare providers. Growth factors include increased diagnosis rates, enhanced research into novel medications and treatment methodologies, and a greater public awareness about mental health. The rising prevalence of mental health disorders coupled with ongoing efforts to destigmatize mental illness can foster market expansion. Emerging opportunities are prevalent in developing therapies targeting treatment-resistant patients and the integration of digital technologies, like AI-driven diagnostics and monitoring systems, that can personalize and optimize treatment regimens. However, the market is constrained by several challenges, including high development costs for new therapies, side effects associated with existing medications, and limited access to mental health care in certain regions. Stigma still attached to mental illnesses can also hinder patient engagement in therapeutic interventions. From an innovation standpoint, potential growth areas include the development of next-generation antipsychotics with fewer side effects, advancements in genomics to offer tailored therapies, and leveraging mobile health applications to track treatment adherence and patient progress. Furthermore, cross-collaboration between pharmaceutical companies, technology firms, and healthcare providers can spur advancement and break market barriers. Continuous market research and adaptation to regulatory changes are essential for capturing market share and driving sustainable growth in this dynamic and vital sector.

KEY MARKET STATISTICS
Base Year [2023] USD 7.89 billion
Estimated Year [2024] USD 8.08 billion
Forecast Year [2030] USD 11.06 billion
CAGR (%) 4.94%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Schizophrenia Therapeutics Market

The Schizophrenia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of schizophrenia disorder among individuals worldwide
    • Government initiatives and campaigns to raise awareness regarding mental health conditions
    • Ongoing research for the development of efficient drugs for schizophrenia
  • Market Restraints
    • High cost of treatment and lack of insurance coverage
  • Market Opportunities
    • Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
    • Advancements in schizophrenia treatment and therapeutics
  • Market Challenges
    • Side effects associated with the medications prescribed for schizophrenia

Porter's Five Forces: A Strategic Tool for Navigating the Schizophrenia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Schizophrenia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Schizophrenia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Schizophrenia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Schizophrenia Therapeutics Market

A detailed market share analysis in the Schizophrenia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Schizophrenia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Schizophrenia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Schizophrenia Therapeutics Market

A strategic analysis of the Schizophrenia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Acadia Pharmaceuticals Inc., Alkermes Plc, Allergan Plc by AbbVie Inc., Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb and Company, Delpor, Inc., Eli Lilly and Company, Gedeon Richter Plc, Johnson & Johnson Services, Inc., Karuna Therapeutics Inc, Lundbeck A/S, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Neurocrine Biosciences, Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Schizophrenia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Second Generation and Third Generation.
  • Based on Administration, market is studied across Injectable and Oral.
  • Based on Distribution Channel, market is studied across Hospital and Pharmacies. The Pharmacies is further studied across Offline and Online.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of schizophrenia disorder among individuals worldwide
      • 5.1.1.2. Government initiatives and campaigns to raise awareness regarding mental health conditions
      • 5.1.1.3. Ongoing research for the development of efficient drugs for schizophrenia
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of insurance coverage
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on personalized medicine for improving drug efficacy in patients with schizophrenia disorder
      • 5.1.3.2. Advancements in schizophrenia treatment and therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the medications prescribed for schizophrenia
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Second Generation
  • 6.3. Third Generation

7. Schizophrenia Therapeutics Market, by Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Schizophrenia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Pharmacies
    • 8.3.1. Offline
    • 8.3.2. Online

9. Americas Schizophrenia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Schizophrenia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Schizophrenia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acadia Pharmaceuticals Inc.
  • 2. Alkermes Plc
  • 3. Allergan Plc by AbbVie Inc.
  • 4. Amneal Pharmaceuticals, LLC
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca plc
  • 7. BioXcel Therapeutics, Inc.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol-Myers Squibb and Company
  • 10. Delpor, Inc.
  • 11. Eli Lilly and Company
  • 12. Gedeon Richter Plc
  • 13. Johnson & Johnson Services, Inc.
  • 14. Karuna Therapeutics Inc
  • 15. Lundbeck A/S
  • 16. Luye Pharma Group Ltd
  • 17. Lyndra Therapeutics Inc
  • 18. Meiji Holdings Co., Ltd.
  • 19. Neurocrine Biosciences, Inc.
  • 20. Otsuka America Pharmaceutical Inc.
  • 21. Pfizer Inc.
  • 22. Reviva Pharmaceuticals Holdings, Inc.
  • 23. Sumitomo Dainippon Pharma Co., Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 66. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 70. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 86. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 90. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 94. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 107. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 111. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 115. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 119. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 123. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 127. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 131. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 135. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 139. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 143. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 147. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 151. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 155. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 163. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 167. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 171. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 175. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACIES, 2018-2030 (USD MILLION)
  • TABLE 187. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 188. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023